← News
Aug 12, 2026 Regulatory
Colorado Launches a State-Sanctioned Ibogaine Research Pilot
HB26-1325 took effect this month, creating a state-run ibogaine research pilot inside Colorado's Behavioral Health Administration — up to five sites studying ibogaine for PTSD, opioid use disorder, and other conditions, building on the state's 2022 Natural Medicine Health Act. It requires mandated cardiac screening and medical oversight (ibogaine carries a real, well-documented arrhythmia risk), coordination with the FDA's IND process, and a benefit-sharing requirement with Indigenous communities historically associated with iboga. This is a research pilot, not legalization — no sites have been picked yet, and ibogaine remains Schedule I federally.
Read at Colorado General Assembly